HighGravityDataModerna — Aug 1, 2025 release
Fiscal 2025 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001682852-25-000041
Showing in the filing
Projected revenue range
“$1.5 to $2.2 billion”
Period
FY2025
Measure
GAAP-tied
Source
Prose
All guidance in this release · 15
Projected revenue range for FY2025
“$1.5 to $2.2 billion”
Revenue for FY2025
“$1.5 to $2.2 billion”
Expected GAAP operating expenses for FY2025
“$5.9 to $6.1 billion”
Expected year-end cash balance for FY2025
“approximately $6 billion”
Year-end cash and investments for FY2025
“approximately $6 billion”
Revenue split for H2 FY2025
“40-50% in the third quarter with the balance in the fourth quarter of 2025”
Revenue split for Q3 FY2025
“40-50%”
Second half 2025 revenue split for Q3 FY2025
“40-50% in the third quarter with the balance in the fourth quarter”
Cost of sales for FY2025
“approximately $1.2 billion”
Research and development expenses for FY2025
“$3.6 to $3.8 billion”
Selling, general and administrative expenses for FY2025
“approximately $1.1 billion”
Income Taxes for FY2025
“negligible”
Tax expense for FY2025
“negligible”
Capital expenditures for FY2025
“approximately $0.3 billion”
Total headcount for FY2025
“under 5,000”
Exhibit 99.1 · the passage around this item
… earlier in the release
ports Second Quarter 2025 Financial Results and Provides Business Updates Reports second quarter revenues of $0.1 billion , GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reduction at the high end, primarily driven by timing of deliveries for contracted revenue into the first quarter of 2026 Improves 2025 expected GAAP operating expenses by approximately $400 million to a range of $5.9 to $6.1 billion Reiterates 2025 expected year-end cash balance of approximately $6 billion Announced three recent U.S. FDA approvals and positive Phase 3 efficacy results for seasonal influenza vaccine CAMBRIDGE, MA / ACCESSWIRE / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine efficacy data and expanded our commercial portfolio with three new U.S. FDA approvals to drive future sales growth," said Stéphane Bancel, Chief Executive Officer of Moderna. “Today, we are updating our 2025 financial framework, reducing the high end of this year's expected revenue range by $300 million due to the timing of shipments. We continue to operate with financial discipline and are improving expected annual operating expenses in 2025 by approximately $400 million. Looking forward, we
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.